Sarepta Therapeutics (AB3A) Stock Price & Analysis
AB3A Stock Chart & Stats
- Day’s Range
- EUR 16.80 - EUR 16.80
- 52-Week Range
- EUR 12.82 - EUR 21.42
- Previous Close
- EUR 16.92
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.76B
- Enterprise Value
- EUR 2.15B
- Total Cash (Recent Filing)
- EUR 788.49M
- Total Debt (Recent Filing)
- EUR 1.05B
- Price to Earnings (P/E)
- ―
- Beta
- 1.16
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Durable PMO Franchise
The PMO franchise provides an established commercial base within DMD, supported by high adherence and a sizable treated population. Its 75% quarterly gross margin and stable demand can help sustain funding for pipeline development while ELEVIDYS adoption evolves.
Improved Operating Discipline
Recent operating profitability and substantial expense reductions show that Sarepta can improve earnings through tighter cost control and portfolio prioritization. This strengthens operating leverage and creates a more resilient foundation for investing in commercial and clinical programs.
Broader ELEVIDYS Clinical Support
Evidence of sustained functional benefit across older ambulatory patients broadens support for ELEVIDYS beyond younger populations. If maintained through continued follow-up, this can reinforce physician confidence, extend the therapy's addressable use, and support longer-term franchise durability.
Bears Say
ELEVIDYS Revenue Pressure
The decline in ELEVIDYS demand is significant because the therapy is central to Sarepta's growth outlook. Management expects Q3 ELEVIDYS revenue and second-half product revenue to be lower, creating an ongoing risk that commercial expansion will not offset near-term weakness.
Persistent Cash Burn
Continued negative operating and free cash flow means Sarepta has not yet demonstrated durable self-funding economics. Persistent cash burn can constrain flexibility for clinical development, commercial investment, and other capital allocation decisions if profitability remains inconsistent.
Regulatory And Program Constraints
Delayed cohort 8 safety data postpones regulatory discussions tied to nonambulatory labeling and leaves important program decisions unresolved. The LGMD clinical hold further limits pipeline progress, increasing dependence on DMD execution and successful regulatory outcomes.
Sarepta Therapeutics News
AB3A FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
What is Sarepta Therapeutics’s market cap?
When is Sarepta Therapeutics’s upcoming earnings report date?
How were Sarepta Therapeutics’s earnings last quarter?
Is Sarepta Therapeutics overvalued?
Does Sarepta Therapeutics pay dividends?
What is Sarepta Therapeutics’s EPS estimate?
How many shares outstanding does Sarepta Therapeutics have?
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sarepta Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Sarepta Therapeutics Stock Smart Score
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael E. Severino
- Employees
- 835
- Website
- www.sarepta.com
- Address
- 215 First Street, Cambridge, MA, 02142, US
Sarepta Therapeutics (AB3A) Earnings & Revenues
AB3A Company Deck
AB3A Earnings Call
Earnings Call SentimentNeutral
The call presented a balanced picture: Sarepta demonstrated strong operational discipline (GAAP and non-GAAP profitability), meaningful cash growth, expense reductions, and progress across its siRNA and regulatory programs — all positive signs. However, a substantial year-over-year revenue decline (34% in Q2) driven by lower ELEVIDYS demand, near-term expectations for modestly lower product revenue in H2, a $39M litigation charge, and timing delays for key safety readouts temper the outlook. Pipeline catalysts and accepted sNDAs provide upside potential, but near-term top-line pressure and regulatory/timing uncertainties leave the narrative mixed.
View all DE:AB3A earnings summariesAB3A Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 5 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |
